ArticleEClinicalMedicine2026
Minimally invasive surgical resection reduces one-year mortality, especially in high-risk colon cancer patients: an emulated trial.
Article in EClinicalMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Comorbidity, older age, frailty and socioeconomic deprivation are associated with higher risk of complications and death following resection for colon cancer. Minimally invasive surgical (MIS) resection is associated with earlier recovery, fewer postoperative complications and potentially lower early mortality than open surgical (OS) resection. We investigated the likelihood of receiving MIS vs OS resection by patient characteristics, and whether MIS resection reduces mortality after elective resection for colon cancer. Methods: We analysed cancer registration data linked to secondary care records of 21,931 patients diagnosed with stage I-III colon cancer in NHS Trusts in England, in 2021 and 2022. We focused on elective operations completed as either MIS resections or OS resections. We used an emulated trial to estimate the impact of MIS resection on one-year mortality (expressed as Average Treatment Effect) compared with OS resection. Inverse-probability-weights with regression adjustment ensured comparability between the surgical groups. Findings: MIS resection was attempted in 18,264 (83.3% of 21,931) patients and completed in 16,271 (74.2% of 21,931), among whom higher levels of deprivation, frailty, comorbidity and stage at diagnosis were independently associated with lower odds of receiving MIS resection. Observed one-year mortality was 7.7% after OS resection (436 deaths among 5660) vs 2.9% after MIS resection (472 deaths among 16,271). In the emulated trial, the average treatment effect of MIS resection was a reduction in one-year mortality from 6.8% to 3.0%; with the largest absolute reductions among patients aged 85 years or more, frail patients, and those with major comorbidities. Interpretation: The emulated trial confirms that MIS resection for colon cancer reduces mortality at one year, compared with OS resection. However, patients in higher-risk groups, who were most likely to benefit from MIS resection, were less likely to receive it. The NHS needs to eliminate ongoing inequalities in optimal surgery for colon cancer. Funding: Cancer Research UK C7923/A29018; Medical Research Council MR/T032448/1 and MR/W021021.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.